Drug Trial Radar · NCT05411237
Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma
Last checked: Nov 19, 2026Latest source record: Jan 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
130
Planned (sponsor's estimate)
Start
Sep 2026
Primary completion
Sep 2029
Study completion Sep 2030
Sponsor
- Lead sponsor
- AIDS Malignancy ConsortiumResearch network
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Jun 9, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is being done to determine if two different anti-cancer drugs, paclitaxel (PTX) and pegylated liposomal doxorubicin (PLD) have similar effects on treating Kaposi Sarcoma (KS) in people living with HIV (human immunodeficiency virus) in sub-Saharan Africa. Patients with HIV-related KS will receive either PTX or PLD once every 3 weeks for a total of six cycles.
Conditions
- Kaposi Sarcoma
- HIV-1-infection
- AIDS-related Kaposi Sarcoma
Interventions
Pegylated liposomal doxorubicinDrug
PLD 20 mg/m2 on Day 1 of every 21-day cycle
PaclitaxelDrug
PTX 100 mg/m2 on Day 1 of every 21-day cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival at 48 weeksTime frame: 48 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.